Skip to main content
Erschienen in: Arthritis Research & Therapy 6/2008

01.12.2008 | Review

Glomerular matrix metalloproteinases and their regulators in the pathogenesis of lupus nephritis

verfasst von: Anders Tveita, Ole Petter Rekvig, Svetlana N Zykova

Erschienen in: Arthritis Research & Therapy | Ausgabe 6/2008

Einloggen, um Zugang zu erhalten

Abstract

Lupus nephritis is a major contributor to morbidity and mortality in systemic lupus erythematosus, but little is known about the pathogenic processes that underlie the progressive decay in renal function. A common finding in lupus nephritis is thickening of glomerular basement membranes associated with immune complex deposition. It has been speculated that alterations in the synthesis or degradation of membrane components might contribute to such changes, and thereby to initiation and progression of nephritis through facilitation of immune complex deposition. Matrix metalloproteinases (MMPs) are enzymes that are intimately involved in the turnover of major glomerular basement membrane constituents, including collagen IV and laminins. Alterations in the expression and activity of MMPs have been described in a number of renal diseases, suggesting their relevance to the pathogenesis of various glomerulopathies. The same is true for their natural inhibitors, the tissue inhibitor of metalloproteinase family. Recent data from our group have identified an increase in proteolytic activity within the glomerulus coinciding with the development of proteinuria in the mouse model of systemic lupus erythematosus. (NXB × NZW)F1 Here we review current understanding of MMP/tissue inhibitor of metalloproteinase function within the kidney, and discuss their possible involvement in the development and progression of lupus nephritis.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat Berden JH, Grootscholten C, Jurgen WC, Vlag van der J: Lupus nephritis: a nucleosome waste disposal defect?. J Nephrol. 2002, 15 (suppl 6): S1-S10.PubMed Berden JH, Grootscholten C, Jurgen WC, Vlag van der J: Lupus nephritis: a nucleosome waste disposal defect?. J Nephrol. 2002, 15 (suppl 6): S1-S10.PubMed
3.
Zurück zum Zitat Kalaaji M, Sturfelt G, Mjelle JE, Nossent H, Rekvig OP: Critical comparative analyses of anti-alpha-actinin and glomerulus-bound antibodies in human and murine lupus nephritis. Arthritis Rheum. 2006, 54: 914-926.CrossRefPubMed Kalaaji M, Sturfelt G, Mjelle JE, Nossent H, Rekvig OP: Critical comparative analyses of anti-alpha-actinin and glomerulus-bound antibodies in human and murine lupus nephritis. Arthritis Rheum. 2006, 54: 914-926.CrossRefPubMed
4.
Zurück zum Zitat Kalaaji M, Fenton KA, Mortensen ES, Olsen R, Sturfelt G, Alm P, Rekvig OP: Glomerular apoptotic nucleosomes are central target structures for nephritogenic antibodies in human SLE nephritis. Kidney Int. 2007, 71: 664-672.CrossRefPubMed Kalaaji M, Fenton KA, Mortensen ES, Olsen R, Sturfelt G, Alm P, Rekvig OP: Glomerular apoptotic nucleosomes are central target structures for nephritogenic antibodies in human SLE nephritis. Kidney Int. 2007, 71: 664-672.CrossRefPubMed
5.
Zurück zum Zitat Mjelle JE, Rekvig OP, Fenton KA: Nucleosomes possess high affinity for glomerular laminin and collagen IV and bind nephritogenic antibodies in murine lupus-like nephritis. Ann Rheum Dis. 2007, 66: 1661-1668.PubMedCentralCrossRefPubMed Mjelle JE, Rekvig OP, Fenton KA: Nucleosomes possess high affinity for glomerular laminin and collagen IV and bind nephritogenic antibodies in murine lupus-like nephritis. Ann Rheum Dis. 2007, 66: 1661-1668.PubMedCentralCrossRefPubMed
6.
Zurück zum Zitat Bergijk EC, Van Alderwegen IE, Baelde HJ, de Heer E, Funabiki K, Miyai H, Killen PD, Kalluri RK, Bruijn JA: Differential expression of collagen IV isoforms in experimental glomerulosclerosis. J Pathol. 1998, 184: 307-315.CrossRefPubMed Bergijk EC, Van Alderwegen IE, Baelde HJ, de Heer E, Funabiki K, Miyai H, Killen PD, Kalluri RK, Bruijn JA: Differential expression of collagen IV isoforms in experimental glomerulosclerosis. J Pathol. 1998, 184: 307-315.CrossRefPubMed
7.
Zurück zum Zitat Peutz-Kootstra CJ, Hansen K, De Heer E, Abrass CK, Bruijn JA: Differential expression of laminin chains and anti-laminin autoantibodies in experimental lupus nephritis. J Pathol. 2000, 192: 404-412.CrossRefPubMed Peutz-Kootstra CJ, Hansen K, De Heer E, Abrass CK, Bruijn JA: Differential expression of laminin chains and anti-laminin autoantibodies in experimental lupus nephritis. J Pathol. 2000, 192: 404-412.CrossRefPubMed
10.
Zurück zum Zitat Imai K, Yokohama Y, Nakanishi I, Ohuchi E, Fujii Y, Nakai N, Okada Y: Matrix metalloproteinase 7 (matrilysin) from human rectal carcinoma cells. Activation of the precursor, interaction with other matrix metalloproteinases and enzymic properties. J Biol Chem. 1995, 270: 6691-6697.CrossRefPubMed Imai K, Yokohama Y, Nakanishi I, Ohuchi E, Fujii Y, Nakai N, Okada Y: Matrix metalloproteinase 7 (matrilysin) from human rectal carcinoma cells. Activation of the precursor, interaction with other matrix metalloproteinases and enzymic properties. J Biol Chem. 1995, 270: 6691-6697.CrossRefPubMed
11.
Zurück zum Zitat McLennan SV, Kelly DJ, Schache M, Waltham M, Dy V, Langham RG, Yue DK, Gilbert RE: Advanced glycation end products decrease mesangial cell MMP-7: a role in matrix accumulation in diabetic nephropathy?. Kidney Int. 2007, 72: 481-488.CrossRefPubMed McLennan SV, Kelly DJ, Schache M, Waltham M, Dy V, Langham RG, Yue DK, Gilbert RE: Advanced glycation end products decrease mesangial cell MMP-7: a role in matrix accumulation in diabetic nephropathy?. Kidney Int. 2007, 72: 481-488.CrossRefPubMed
12.
Zurück zum Zitat Rao VH, Lees GE, Kashtan CE, Delimont DC, Singh R, Meehan DT, Bhattacharya G, Berridge BR, Cosgrove D: Dysregulation of renal MMP-3 and MMP-7 in canine X-linked Alport syndrome. Pediatr Nephrol. 2005, 20: 732-739.CrossRefPubMed Rao VH, Lees GE, Kashtan CE, Delimont DC, Singh R, Meehan DT, Bhattacharya G, Berridge BR, Cosgrove D: Dysregulation of renal MMP-3 and MMP-7 in canine X-linked Alport syndrome. Pediatr Nephrol. 2005, 20: 732-739.CrossRefPubMed
13.
Zurück zum Zitat Mignatti P: Extracellular matrix remodeling by metalloproteinases and plasminogen activators. Kidney Int Suppl. 1995, 49: S12-S14.PubMed Mignatti P: Extracellular matrix remodeling by metalloproteinases and plasminogen activators. Kidney Int Suppl. 1995, 49: S12-S14.PubMed
14.
Zurück zum Zitat Haro H, Crawford HC, Fingleton B, Shinomiya K, Spengler DM, Matrisian LM: Matrix metalloproteinase-7-dependent release of tumor necrosis factor-alpha in a model of herniated disc resorption. J Clin Invest. 2000, 105: 143-150.PubMedCentralCrossRefPubMed Haro H, Crawford HC, Fingleton B, Shinomiya K, Spengler DM, Matrisian LM: Matrix metalloproteinase-7-dependent release of tumor necrosis factor-alpha in a model of herniated disc resorption. J Clin Invest. 2000, 105: 143-150.PubMedCentralCrossRefPubMed
15.
Zurück zum Zitat Wang FQ, So J, Reierstad S, Fishman DA: Matrilysin (MMP-7) promotes invasion of ovarian cancer cells by activation of progelatinase. Int J Cancer. 2005, 114: 19-31.CrossRefPubMed Wang FQ, So J, Reierstad S, Fishman DA: Matrilysin (MMP-7) promotes invasion of ovarian cancer cells by activation of progelatinase. Int J Cancer. 2005, 114: 19-31.CrossRefPubMed
16.
Zurück zum Zitat Martin J, Knowlden J, Davies M, Williams JD: Identification and independent regulation of human mesangial cell metalloproteinases. Kidney Int. 1994, 46: 877-885.CrossRefPubMed Martin J, Knowlden J, Davies M, Williams JD: Identification and independent regulation of human mesangial cell metalloproteinases. Kidney Int. 1994, 46: 877-885.CrossRefPubMed
17.
Zurück zum Zitat Lenz O, Striker LJ, Jacot TA, Elliot SJ, Killen PD, Striker GE: Glomerular endothelial cells synthesize collagens but little gelatinase A and B. J Am Soc Nephrol. 1998, 9: 2040-2047.PubMed Lenz O, Striker LJ, Jacot TA, Elliot SJ, Killen PD, Striker GE: Glomerular endothelial cells synthesize collagens but little gelatinase A and B. J Am Soc Nephrol. 1998, 9: 2040-2047.PubMed
18.
Zurück zum Zitat Camp TM, Smiley LM, Hayden MR, Tyagi SC: Mechanism of matrix accumulation and glomerulosclerosis in spontaneously hypertensive rats. J Hypertens. 2003, 21: 1719-1727.CrossRefPubMed Camp TM, Smiley LM, Hayden MR, Tyagi SC: Mechanism of matrix accumulation and glomerulosclerosis in spontaneously hypertensive rats. J Hypertens. 2003, 21: 1719-1727.CrossRefPubMed
19.
Zurück zum Zitat Zhang ZG, Liu XG, Chen GP, Zhang XR, Guo MY: Significance of MMP-2 and TIMP-2 mRNA expressions on glomerular cells in the development of glomerulosclerosis. Chin Med Sci J. 2004, 19: 84-88.PubMed Zhang ZG, Liu XG, Chen GP, Zhang XR, Guo MY: Significance of MMP-2 and TIMP-2 mRNA expressions on glomerular cells in the development of glomerulosclerosis. Chin Med Sci J. 2004, 19: 84-88.PubMed
20.
Zurück zum Zitat Urushihara M, Kagami S, Kuhara T, Tamaki T, Kuroda Y: Glomerular distribution and gelatinolytic activity of matrix metalloproteinases in human glomerulonephritis. Nephrol Dial Transplant. 2002, 17: 1189-1196.CrossRefPubMed Urushihara M, Kagami S, Kuhara T, Tamaki T, Kuroda Y: Glomerular distribution and gelatinolytic activity of matrix metalloproteinases in human glomerulonephritis. Nephrol Dial Transplant. 2002, 17: 1189-1196.CrossRefPubMed
21.
Zurück zum Zitat Tveita A, Rekvig OP, Zykova SN: Increased glomerular matrix metalloproteinase activity in murine lupus nephritis. Kidney Int. 2008, 74: 1150-1158.CrossRefPubMed Tveita A, Rekvig OP, Zykova SN: Increased glomerular matrix metalloproteinase activity in murine lupus nephritis. Kidney Int. 2008, 74: 1150-1158.CrossRefPubMed
22.
Zurück zum Zitat Murphy G, Willenbrock F: Tissue inhibitors of matrix metalloendopeptidases. Methods Enzymol. 1995, 248: 496-510.CrossRefPubMed Murphy G, Willenbrock F: Tissue inhibitors of matrix metalloendopeptidases. Methods Enzymol. 1995, 248: 496-510.CrossRefPubMed
23.
Zurück zum Zitat Zaoui P, Barro C, Maynard C, Descotes JL, Maurizi-Balzan J, Cordonnier DJ, Morel F: Inter-regulated balance between gelatinases and tissue inhibitor (TIMP-1) in isolated human glomeruli. Ren Fail. 1998, 20: 201-209.CrossRefPubMed Zaoui P, Barro C, Maynard C, Descotes JL, Maurizi-Balzan J, Cordonnier DJ, Morel F: Inter-regulated balance between gelatinases and tissue inhibitor (TIMP-1) in isolated human glomeruli. Ren Fail. 1998, 20: 201-209.CrossRefPubMed
24.
Zurück zum Zitat Han SY, Jee YH, Han KH, Kang YS, Kim HK, Han JY, Kim YS, Cha DR: An imbalance between matrix metalloproteinase-2 and tissue inhibitor of matrix metalloproteinase-2 contributes to the development of early diabetic nephropathy. Nephrol Dial Transplant. 2006, 21: 2406-2416.CrossRefPubMed Han SY, Jee YH, Han KH, Kang YS, Kim HK, Han JY, Kim YS, Cha DR: An imbalance between matrix metalloproteinase-2 and tissue inhibitor of matrix metalloproteinase-2 contributes to the development of early diabetic nephropathy. Nephrol Dial Transplant. 2006, 21: 2406-2416.CrossRefPubMed
25.
Zurück zum Zitat Chromek M, Tullus K, Lundahl J, Brauner A: Tissue inhibitor of metalloproteinase 1 activates normal human granulocytes, protects them from apoptosis, and blocks their transmigration during inflammation. Infect Immun. 2004, 72: 82-88.PubMedCentralCrossRefPubMed Chromek M, Tullus K, Lundahl J, Brauner A: Tissue inhibitor of metalloproteinase 1 activates normal human granulocytes, protects them from apoptosis, and blocks their transmigration during inflammation. Infect Immun. 2004, 72: 82-88.PubMedCentralCrossRefPubMed
26.
Zurück zum Zitat Chirco R, Liu XW, Jung KK, Kim HR: Novel functions of TIMPs in cell signaling. Cancer Metastasis Rev. 2006, 25: 99-113.CrossRefPubMed Chirco R, Liu XW, Jung KK, Kim HR: Novel functions of TIMPs in cell signaling. Cancer Metastasis Rev. 2006, 25: 99-113.CrossRefPubMed
27.
Zurück zum Zitat Daniel C, Duffield J, Brunner T, Steinmann-Niggli K, Lods N, Marti HP: Matrix metalloproteinase inhibitors cause cell cycle arrest and apoptosis in glomerular mesangial cells. J Pharmacol Exp Ther. 2001, 297: 57-68.PubMed Daniel C, Duffield J, Brunner T, Steinmann-Niggli K, Lods N, Marti HP: Matrix metalloproteinase inhibitors cause cell cycle arrest and apoptosis in glomerular mesangial cells. J Pharmacol Exp Ther. 2001, 297: 57-68.PubMed
28.
Zurück zum Zitat Liu XW, Taube ME, Jung KK, Dong Z, Lee YJ, Roshy S, Sloane BF, Fridman R, Kim HR: Tissue inhibitor of metalloproteinase-1 protects human breast epithelial cells from extrinsic cell death: a potential oncogenic activity of tissue inhibitor of metalloproteinase-1. Cancer Res. 2005, 65: 898-906.PubMed Liu XW, Taube ME, Jung KK, Dong Z, Lee YJ, Roshy S, Sloane BF, Fridman R, Kim HR: Tissue inhibitor of metalloproteinase-1 protects human breast epithelial cells from extrinsic cell death: a potential oncogenic activity of tissue inhibitor of metalloproteinase-1. Cancer Res. 2005, 65: 898-906.PubMed
29.
Zurück zum Zitat Liu XW, Bernardo MM, Fridman R, Kim HR: Tissue inhibitor of metalloproteinase-1 protects human breast epithelial cells against intrinsic apoptotic cell death via the focal adhesion kinase/phosphatidylinositol 3-kinase and MAPK signaling pathway. J Biol Chem. 2003, 278: 40364-40372.CrossRefPubMed Liu XW, Bernardo MM, Fridman R, Kim HR: Tissue inhibitor of metalloproteinase-1 protects human breast epithelial cells against intrinsic apoptotic cell death via the focal adhesion kinase/phosphatidylinositol 3-kinase and MAPK signaling pathway. J Biol Chem. 2003, 278: 40364-40372.CrossRefPubMed
30.
Zurück zum Zitat Guedez L, Stetler-Stevenson WG, Wolff L, Wang J, Fukushima P, Mansoor A, Stetler-Stevenson M: In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1. J Clin Invest. 1998, 102: 2002-2010.PubMedCentralCrossRefPubMed Guedez L, Stetler-Stevenson WG, Wolff L, Wang J, Fukushima P, Mansoor A, Stetler-Stevenson M: In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1. J Clin Invest. 1998, 102: 2002-2010.PubMedCentralCrossRefPubMed
31.
Zurück zum Zitat Rho SB, Chung BM, Lee JH: TIMP-1 regulates cell proliferation by interacting with the ninth zinc finger domain of PLZF. J Cell Biochem. 2007, 101: 57-67.CrossRefPubMed Rho SB, Chung BM, Lee JH: TIMP-1 regulates cell proliferation by interacting with the ninth zinc finger domain of PLZF. J Cell Biochem. 2007, 101: 57-67.CrossRefPubMed
32.
Zurück zum Zitat Ritter LM, Garfield SH, Thorgeirsson UP: Tissue inhibitor of metalloproteinases-1 (TIMP-1) binds to the cell surface and translocates to the nucleus of human MCF-7 breast carcinoma cells. Biochem Biophysic Res Commun. 1999, 257: 494-499.CrossRef Ritter LM, Garfield SH, Thorgeirsson UP: Tissue inhibitor of metalloproteinases-1 (TIMP-1) binds to the cell surface and translocates to the nucleus of human MCF-7 breast carcinoma cells. Biochem Biophysic Res Commun. 1999, 257: 494-499.CrossRef
34.
Zurück zum Zitat Si-Tayeb K, Monvoisin A, Mazzocco C, Lepreux S, Decossas M, Cubel G, Taras D, Blanc JF, Robinson DR, Rosenbaum J: Matrix metalloproteinase 3 is present in the cell nucleus and is involved in apoptosis. Am J Pathol. 2006, 169: 1390-1401.PubMedCentralCrossRefPubMed Si-Tayeb K, Monvoisin A, Mazzocco C, Lepreux S, Decossas M, Cubel G, Taras D, Blanc JF, Robinson DR, Rosenbaum J: Matrix metalloproteinase 3 is present in the cell nucleus and is involved in apoptosis. Am J Pathol. 2006, 169: 1390-1401.PubMedCentralCrossRefPubMed
35.
Zurück zum Zitat Baker AH, Zaltsman AB, George SJ, Newby AC: Divergent effects of tissue inhibitor of metalloproteinase-1, -2, or -3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro. TIMP-3 promotes apoptosis. J Clin Invest. 1998, 101: 1478-1487.PubMedCentralCrossRefPubMed Baker AH, Zaltsman AB, George SJ, Newby AC: Divergent effects of tissue inhibitor of metalloproteinase-1, -2, or -3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro. TIMP-3 promotes apoptosis. J Clin Invest. 1998, 101: 1478-1487.PubMedCentralCrossRefPubMed
36.
Zurück zum Zitat Smith MR, Kung H, Durum SK, Colburn NH, Sun Y: TIMP-3 induces cell death by stabilizing TNF-alpha receptors on the surface of human colon carcinoma cells. Cytokine. 1997, 9: 770-780.CrossRefPubMed Smith MR, Kung H, Durum SK, Colburn NH, Sun Y: TIMP-3 induces cell death by stabilizing TNF-alpha receptors on the surface of human colon carcinoma cells. Cytokine. 1997, 9: 770-780.CrossRefPubMed
37.
Zurück zum Zitat Ahonen M, Poukkula M, Baker AH, Kashiwagi M, Nagase H, Eriksson JE, Kahari VM: Tissue inhibitor of metalloproteinases-3 induces apoptosis in melanoma cells by stabilization of death receptors. Oncogene. 2003, 22: 2121-2134.CrossRefPubMed Ahonen M, Poukkula M, Baker AH, Kashiwagi M, Nagase H, Eriksson JE, Kahari VM: Tissue inhibitor of metalloproteinases-3 induces apoptosis in melanoma cells by stabilization of death receptors. Oncogene. 2003, 22: 2121-2134.CrossRefPubMed
38.
Zurück zum Zitat Finan KM, Hodge G, Reynolds AM, Hodge S, Holmes MD, Baker AH, Reynolds PN: In vitro susceptibility to the pro-apoptotic effects of TIMP-3 gene delivery translates to greater in vivo efficacy versus gene delivery for TIMPs-1 or -2. Lung Cancer. 2006, 53: 273-284.CrossRefPubMed Finan KM, Hodge G, Reynolds AM, Hodge S, Holmes MD, Baker AH, Reynolds PN: In vitro susceptibility to the pro-apoptotic effects of TIMP-3 gene delivery translates to greater in vivo efficacy versus gene delivery for TIMPs-1 or -2. Lung Cancer. 2006, 53: 273-284.CrossRefPubMed
39.
Zurück zum Zitat Nakajima A, Hirai H, Kayagaki N, Yoshino S, Hirose S, Yagita H, Okumura K: Treatment of lupus in NZB/W F1 mice with monoclonal antibody against Fas ligand. J Autoimmun. 2000, 14: 151-157.CrossRefPubMed Nakajima A, Hirai H, Kayagaki N, Yoshino S, Hirose S, Yagita H, Okumura K: Treatment of lupus in NZB/W F1 mice with monoclonal antibody against Fas ligand. J Autoimmun. 2000, 14: 151-157.CrossRefPubMed
40.
Zurück zum Zitat Andrews KL, Betsuyaku T, Rogers S, Shipley JM, Senior RM, Miner JH: Gelatinase B (MMP-9) is not essential in the normal kidney and does not influence progression of renal disease in a mouse model of Alport syndrome. Am J Pathol. 2000, 157: 303-311.PubMedCentralCrossRefPubMed Andrews KL, Betsuyaku T, Rogers S, Shipley JM, Senior RM, Miner JH: Gelatinase B (MMP-9) is not essential in the normal kidney and does not influence progression of renal disease in a mouse model of Alport syndrome. Am J Pathol. 2000, 157: 303-311.PubMedCentralCrossRefPubMed
41.
Zurück zum Zitat Zeisberg M, Khurana M, Rao VH, Cosgrove D, Rougier JP, Werner MC, Shield CF, Werb Z, Kalluri R: Stage-specific action of matrix metalloproteinases influences progressive hereditary kidney disease. PLoS Med. 2006, 3: e100-PubMedCentralCrossRefPubMed Zeisberg M, Khurana M, Rao VH, Cosgrove D, Rougier JP, Werner MC, Shield CF, Werb Z, Kalluri R: Stage-specific action of matrix metalloproteinases influences progressive hereditary kidney disease. PLoS Med. 2006, 3: e100-PubMedCentralCrossRefPubMed
42.
Zurück zum Zitat Galis ZS, Sukhova GK, Libby P: Microscopic localization of active proteases by in situ zymography: detection of matrix metalloproteinase activity in vascular tissue. FASEB J. 1995, 9: 974-980.PubMed Galis ZS, Sukhova GK, Libby P: Microscopic localization of active proteases by in situ zymography: detection of matrix metalloproteinase activity in vascular tissue. FASEB J. 1995, 9: 974-980.PubMed
43.
Zurück zum Zitat Nakamura T, Ebihara I, Osada S, Takahashi T, Yamamoto M, Tomino Y, Koide H: Gene expression of metalloproteinases and their inhibitor in renal tissue of New Zealand black/white F1 mice. Clin Sci (Lond). 1993, 85: 295-301.CrossRef Nakamura T, Ebihara I, Osada S, Takahashi T, Yamamoto M, Tomino Y, Koide H: Gene expression of metalloproteinases and their inhibitor in renal tissue of New Zealand black/white F1 mice. Clin Sci (Lond). 1993, 85: 295-301.CrossRef
44.
Zurück zum Zitat Faber-Elmann A, Sthoeger Z, Tcherniack A, Dayan M, Mozes E: Activity of matrix metalloproteinase-9 is elevated in sera of patients with systemic lupus erythematosus. Clin Exp Immunol. 2002, 127: 393-398.PubMedCentralCrossRefPubMed Faber-Elmann A, Sthoeger Z, Tcherniack A, Dayan M, Mozes E: Activity of matrix metalloproteinase-9 is elevated in sera of patients with systemic lupus erythematosus. Clin Exp Immunol. 2002, 127: 393-398.PubMedCentralCrossRefPubMed
45.
Zurück zum Zitat Keyszer G, Lambiri I, Nagel R, Keysser C, Keysser M, Gromnica-Ihle E, Franz J, Burmester GR, Jung K: Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers. J Rheumatol. 1999, 26: 251-258.PubMed Keyszer G, Lambiri I, Nagel R, Keysser C, Keysser M, Gromnica-Ihle E, Franz J, Burmester GR, Jung K: Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers. J Rheumatol. 1999, 26: 251-258.PubMed
46.
Zurück zum Zitat Kotajima L, Aotsuka S, Fujimani M, Okawa-Takatsuji M, Kinoshita M, Sumiya M, Obata K: Increased levels of matrix metalloproteinase-3 in sera from patients with active lupus nephritis. Clin Exp Rheumatol. 1998, 16: 409-415.PubMed Kotajima L, Aotsuka S, Fujimani M, Okawa-Takatsuji M, Kinoshita M, Sumiya M, Obata K: Increased levels of matrix metalloproteinase-3 in sera from patients with active lupus nephritis. Clin Exp Rheumatol. 1998, 16: 409-415.PubMed
47.
Zurück zum Zitat Zucker S, Hymowitz M, Conner C, Zarrabi HM, Hurewitz AN, Matrisian L, Boyd D, Nicolson G, Montana S: Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clinical and experimental applications. Ann N Y Acad Sci. 1999, 878: 212-227.CrossRefPubMed Zucker S, Hymowitz M, Conner C, Zarrabi HM, Hurewitz AN, Matrisian L, Boyd D, Nicolson G, Montana S: Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clinical and experimental applications. Ann N Y Acad Sci. 1999, 878: 212-227.CrossRefPubMed
48.
Zurück zum Zitat Makowski GS, Ramsby ML: Concentrations of circulating matrix metalloproteinase 9 inversely correlate with autoimmune antibodies to double stranded DNA: implications for monitoring disease activity in systemic lupus erythematosus. Mol Pathol. 2003, 56: 244-247.PubMedCentralCrossRefPubMed Makowski GS, Ramsby ML: Concentrations of circulating matrix metalloproteinase 9 inversely correlate with autoimmune antibodies to double stranded DNA: implications for monitoring disease activity in systemic lupus erythematosus. Mol Pathol. 2003, 56: 244-247.PubMedCentralCrossRefPubMed
49.
Zurück zum Zitat Zucker S, Mian N, Drews M, Conner C, Davidson A, Miller F, Birembaut P, Nawrocki B, Docherty AJ, Greenwald RA, Grimson R, Barland P: Increased serum stromelysin-1 levels in systemic lupus erythematosus: lack of correlation with disease activity. J Rheumatol. 1999, 26: 78-80.PubMed Zucker S, Mian N, Drews M, Conner C, Davidson A, Miller F, Birembaut P, Nawrocki B, Docherty AJ, Greenwald RA, Grimson R, Barland P: Increased serum stromelysin-1 levels in systemic lupus erythematosus: lack of correlation with disease activity. J Rheumatol. 1999, 26: 78-80.PubMed
50.
Zurück zum Zitat Ainiala H, Hietaharju A, Dastidar P, Loukkola J, Lehtimaki T, Peltola J, Korpela M, Heinonen T, Nikkari ST: Increased serum matrix metalloproteinase 9 levels in systemic lupus erythematosus patients with neuropsychiatric manifestations and brain magnetic resonance imaging abnormalities. Arthritis Rheum. 2004, 50: 858-865.CrossRefPubMed Ainiala H, Hietaharju A, Dastidar P, Loukkola J, Lehtimaki T, Peltola J, Korpela M, Heinonen T, Nikkari ST: Increased serum matrix metalloproteinase 9 levels in systemic lupus erythematosus patients with neuropsychiatric manifestations and brain magnetic resonance imaging abnormalities. Arthritis Rheum. 2004, 50: 858-865.CrossRefPubMed
51.
Zurück zum Zitat Trysberg E, Blennow K, Zachrisson O, Tarkowski A: Intrathecal levels of matrix metalloproteinases in systemic lupus erythematosus with central nervous system engagement. Arthritis Res Ther. 2004, 6: R551-R556.PubMedCentralCrossRefPubMed Trysberg E, Blennow K, Zachrisson O, Tarkowski A: Intrathecal levels of matrix metalloproteinases in systemic lupus erythematosus with central nervous system engagement. Arthritis Res Ther. 2004, 6: R551-R556.PubMedCentralCrossRefPubMed
52.
Zurück zum Zitat Mun-Bryce S, Rosenberg GA: Gelatinase B modulates selective opening of the blood-brain barrier during inflammation. Am J Physiol. 1998, 274: R1203-R1211.PubMed Mun-Bryce S, Rosenberg GA: Gelatinase B modulates selective opening of the blood-brain barrier during inflammation. Am J Physiol. 1998, 274: R1203-R1211.PubMed
53.
Zurück zum Zitat Hu J, Steen Van den PE, Sang QX, Opdenakker G: Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discov. 2007, 6: 480-498.CrossRefPubMed Hu J, Steen Van den PE, Sang QX, Opdenakker G: Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discov. 2007, 6: 480-498.CrossRefPubMed
54.
Zurück zum Zitat Bagchus WM, Hoedemaeker PJ, Rozing J, Bakker WW: Glomerulonephritis induced by monoclonal anti-Thy 1.1 antibodies. A sequential histological and ultrastructural study in the rat. Lab Invest. 1986, 55: 680-687.PubMed Bagchus WM, Hoedemaeker PJ, Rozing J, Bakker WW: Glomerulonephritis induced by monoclonal anti-Thy 1.1 antibodies. A sequential histological and ultrastructural study in the rat. Lab Invest. 1986, 55: 680-687.PubMed
55.
Zurück zum Zitat Heymann W, Hackel DB, Harwood S, Wilson SG, Hunter JL: Production of nephrotic syndrome in rats by Freund's adjuvants and rat kidney suspensions. Proc Soc Exp Biol Med. 1959, 100: 660-664.CrossRefPubMed Heymann W, Hackel DB, Harwood S, Wilson SG, Hunter JL: Production of nephrotic syndrome in rats by Freund's adjuvants and rat kidney suspensions. Proc Soc Exp Biol Med. 1959, 100: 660-664.CrossRefPubMed
56.
Zurück zum Zitat Gonzalez-Avila G, Iturria C, Vadillo-Ortega F, Ovalle C, Montano M: Changes in matrix metalloproteinases during the evolution of interstitial renal fibrosis in a rat experimental model. Pathobiology. 1998, 66: 196-204.CrossRefPubMed Gonzalez-Avila G, Iturria C, Vadillo-Ortega F, Ovalle C, Montano M: Changes in matrix metalloproteinases during the evolution of interstitial renal fibrosis in a rat experimental model. Pathobiology. 1998, 66: 196-204.CrossRefPubMed
57.
Zurück zum Zitat Iimura O, Takahashi H, Yashiro T, Madoiwa S, Sakata Y, Asano Y, Kusano E: Effect of ureteral obstruction on matrix metalloproteinase-2 in rat renal cortex. Clin Exp Nephrol. 2004, 8: 223-229.CrossRefPubMed Iimura O, Takahashi H, Yashiro T, Madoiwa S, Sakata Y, Asano Y, Kusano E: Effect of ureteral obstruction on matrix metalloproteinase-2 in rat renal cortex. Clin Exp Nephrol. 2004, 8: 223-229.CrossRefPubMed
58.
Zurück zum Zitat Zoja C, Abbate M, Remuzzi G: Progression of chronic kidney disease: insights from animal models. Curr Opin Nephrol Hypertens. 2006, 15: 250-257.CrossRefPubMed Zoja C, Abbate M, Remuzzi G: Progression of chronic kidney disease: insights from animal models. Curr Opin Nephrol Hypertens. 2006, 15: 250-257.CrossRefPubMed
59.
Zurück zum Zitat Harendza S, Schneider A, Helmchen U, Stahl RA: Extracellular matrix deposition and cell proliferation in a model of chronic glomerulonephritis in the rat. Nephrol Dial Transplant. 1999, 14: 2873-2879.CrossRefPubMed Harendza S, Schneider A, Helmchen U, Stahl RA: Extracellular matrix deposition and cell proliferation in a model of chronic glomerulonephritis in the rat. Nephrol Dial Transplant. 1999, 14: 2873-2879.CrossRefPubMed
60.
Zurück zum Zitat Hayashi K, Horikoshi S, Osada S, Shofuda K, Shirato I, Tomino Y: Macrophage-derived MT1-MMP and increased MMP-2 activity are associated with glomerular damage in crescentic glomerulonephritis. J Pathol. 2000, 191: 299-305.CrossRefPubMed Hayashi K, Horikoshi S, Osada S, Shofuda K, Shirato I, Tomino Y: Macrophage-derived MT1-MMP and increased MMP-2 activity are associated with glomerular damage in crescentic glomerulonephritis. J Pathol. 2000, 191: 299-305.CrossRefPubMed
61.
Zurück zum Zitat Tomita M, Koike H, Han GD, Shimizu F, Kawachi H: Decreased collagen-degrading activity could be a marker of prolonged mesangial matrix expansion. Clin Exp Nephrol. 2004, 8: 17-26.CrossRefPubMed Tomita M, Koike H, Han GD, Shimizu F, Kawachi H: Decreased collagen-degrading activity could be a marker of prolonged mesangial matrix expansion. Clin Exp Nephrol. 2004, 8: 17-26.CrossRefPubMed
62.
Zurück zum Zitat Lutz J, Yao Y, Song E, Antus B, Hamar P, Liu S, Heemann U: Inhibition of matrix metalloproteinases during chronic allograft nephropathy in rats. Transplantation. 2005, 79: 655-661.CrossRefPubMed Lutz J, Yao Y, Song E, Antus B, Hamar P, Liu S, Heemann U: Inhibition of matrix metalloproteinases during chronic allograft nephropathy in rats. Transplantation. 2005, 79: 655-661.CrossRefPubMed
63.
Zurück zum Zitat Steinmann-Niggli K, Ziswiler R, Kung M, Marti HP: Inhibition of matrix metalloproteinases attenuates anti-Thy1.1 nephritis. J Am Soc Nephrol. 1998, 9: 397-407.PubMed Steinmann-Niggli K, Ziswiler R, Kung M, Marti HP: Inhibition of matrix metalloproteinases attenuates anti-Thy1.1 nephritis. J Am Soc Nephrol. 1998, 9: 397-407.PubMed
64.
Zurück zum Zitat Marti HP: The role of matrix metalloproteinases in the activation of mesangial cells. Transplant Immunol. 2002, 9: 97-100.CrossRef Marti HP: The role of matrix metalloproteinases in the activation of mesangial cells. Transplant Immunol. 2002, 9: 97-100.CrossRef
65.
Zurück zum Zitat Turck J, Pollock AS, Lee LK, Marti HP, Lovett DH: Matrix metalloproteinase 2 (gelatinase A) regulates glomerular mesangial cell proliferation and differentiation. J Biol Chem. 1996, 271: 15074-15083.CrossRefPubMed Turck J, Pollock AS, Lee LK, Marti HP, Lovett DH: Matrix metalloproteinase 2 (gelatinase A) regulates glomerular mesangial cell proliferation and differentiation. J Biol Chem. 1996, 271: 15074-15083.CrossRefPubMed
66.
Zurück zum Zitat Kwan JA, Schulze CJ, Wang W, Leon H, Sariahmetoglu M, Sung M, Sawicka J, Sims DE, Sawicki G, Schulz R: Matrix metalloproteinase-2 (MMP-2) is present in the nucleus of cardiac myocytes and is capable of cleaving poly (ADP-ribose) polymerase (PARP) in vitro. FASEB J. 2004, 18: 690-692.PubMed Kwan JA, Schulze CJ, Wang W, Leon H, Sariahmetoglu M, Sung M, Sawicka J, Sims DE, Sawicki G, Schulz R: Matrix metalloproteinase-2 (MMP-2) is present in the nucleus of cardiac myocytes and is capable of cleaving poly (ADP-ribose) polymerase (PARP) in vitro. FASEB J. 2004, 18: 690-692.PubMed
67.
Zurück zum Zitat Wang W, Schulze CJ, Suarez-Pinzon WL, Dyck JR, Sawicki G, Schulz R: Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury. Circulation. 2002, 106: 1543-1549.CrossRefPubMed Wang W, Schulze CJ, Suarez-Pinzon WL, Dyck JR, Sawicki G, Schulz R: Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury. Circulation. 2002, 106: 1543-1549.CrossRefPubMed
68.
Zurück zum Zitat Nelissen I, Martens E, Steen Van den PE, Proost P, Ronsse I, Opdenakker G: Gelatinase B/matrix metalloproteinase-9 cleaves interferon-beta and is a target for immunotherapy. Brain. 2003, 126: 1371-1381.CrossRefPubMed Nelissen I, Martens E, Steen Van den PE, Proost P, Ronsse I, Opdenakker G: Gelatinase B/matrix metalloproteinase-9 cleaves interferon-beta and is a target for immunotherapy. Brain. 2003, 126: 1371-1381.CrossRefPubMed
69.
Zurück zum Zitat Opdenakker G, Dillen C, Fiten P, Martens E, Van Aelst I, Steen Van den PE, Nelissen I, Starckx S, Descamps FJ, Hu J, Piccard H, Van Damme J, Wormald MR, Rudd PM, Dwek RA: Remnant epitopes, autoimmunity and glycosylation. Biochim Biophys Acta. 2006, 1760: 610-615.CrossRefPubMed Opdenakker G, Dillen C, Fiten P, Martens E, Van Aelst I, Steen Van den PE, Nelissen I, Starckx S, Descamps FJ, Hu J, Piccard H, Van Damme J, Wormald MR, Rudd PM, Dwek RA: Remnant epitopes, autoimmunity and glycosylation. Biochim Biophys Acta. 2006, 1760: 610-615.CrossRefPubMed
70.
Zurück zum Zitat Opdenakker G, Steen Van den PE, Van Damme J: Gelatinase B: a tuner and amplifier of immune functions. Trends Immunol. 2001, 22: 571-579.CrossRefPubMed Opdenakker G, Steen Van den PE, Van Damme J: Gelatinase B: a tuner and amplifier of immune functions. Trends Immunol. 2001, 22: 571-579.CrossRefPubMed
71.
72.
Zurück zum Zitat Lim EJ, Lee SH, Lee JG, Kim JR, Yun SS, Baek SH, Lee C: Toll-like receptor 9 dependent activation of MAPK and NF-kB is required for the CpG ODN-induced matrix metalloproteinase-9 expression. Exp Mol Med. 2007, 39: 239-245.CrossRefPubMed Lim EJ, Lee SH, Lee JG, Kim JR, Yun SS, Baek SH, Lee C: Toll-like receptor 9 dependent activation of MAPK and NF-kB is required for the CpG ODN-induced matrix metalloproteinase-9 expression. Exp Mol Med. 2007, 39: 239-245.CrossRefPubMed
73.
Zurück zum Zitat Merrell MA, Ilvesaro JM, Lehtonen N, Sorsa T, Gehrs B, Rosenthal E, Chen D, Shackley B, Harris KW, Selander KS: Toll-like receptor 9 agonists promote cellular invasion by increasing matrix metalloproteinase activity. Mol Cancer Res. 2006, 4: 437-447.CrossRefPubMed Merrell MA, Ilvesaro JM, Lehtonen N, Sorsa T, Gehrs B, Rosenthal E, Chen D, Shackley B, Harris KW, Selander KS: Toll-like receptor 9 agonists promote cellular invasion by increasing matrix metalloproteinase activity. Mol Cancer Res. 2006, 4: 437-447.CrossRefPubMed
74.
Zurück zum Zitat Gaipl US, Voll RE, Sheriff A, Franz S, Kalden JR, Herrmann M: Impaired clearance of dying cells in systemic lupus erythematosus. Autoimmun Rev. 2005, 4: 189-194.CrossRefPubMed Gaipl US, Voll RE, Sheriff A, Franz S, Kalden JR, Herrmann M: Impaired clearance of dying cells in systemic lupus erythematosus. Autoimmun Rev. 2005, 4: 189-194.CrossRefPubMed
75.
Zurück zum Zitat Lorenz HM, Herrmann M, Winkler T, Gaipl U, Kalden JR: Role of apoptosis in autoimmunity. Apoptosis. 2000, 5: 443-449.CrossRefPubMed Lorenz HM, Herrmann M, Winkler T, Gaipl U, Kalden JR: Role of apoptosis in autoimmunity. Apoptosis. 2000, 5: 443-449.CrossRefPubMed
Metadaten
Titel
Glomerular matrix metalloproteinases and their regulators in the pathogenesis of lupus nephritis
verfasst von
Anders Tveita
Ole Petter Rekvig
Svetlana N Zykova
Publikationsdatum
01.12.2008
Verlag
BioMed Central
Erschienen in
Arthritis Research & Therapy / Ausgabe 6/2008
Elektronische ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar2532

Weitere Artikel der Ausgabe 6/2008

Arthritis Research & Therapy 6/2008 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.